Tables S2 and S3. Severity index scoring system.
Based on the clinical description of the patients carrying PTEN germline mutations, the severity scores were created according to the number of sites affected as well as the presence of mental retardation/ development delay (MR/DD). The presence of macrocephaly was recorded but not included in the severity index score, as macrocephaly was seen in almost every subject, with the chance that it was not recorded in others. For each site affected by benign tumours or lesions it was assigned one point, two points for each site affected by malignant tumours, and one point for the presence of mental retardation. The severity index score is the sum of these numbers. Patients who scored one to three were classified as "mild", four to five as "moderate" and six or above as "severe".
The choice of mutations to analyse has been made based on the "index score average" resulting from the average of the scores of all patients carrying the same PTEN mutation. It should be noted that the characterised PTEN mutants associated with severe phenotypes (see figure 4 ) were selected at a mid-point of the progression of the project and that the data tabulated here contain very recently published information added since that time. Efforts have been made to minimise the chances of double counting but this cannot be excluded. Table S Antibody complexes were detected by 1 hour incubation at RT with HRP conjugated secondary antibodies (Vector Labs). Blots were developed with ECL plus (Millipore) and chemiluminescence imaged directly using an ImageQuant LAS4000 imaging system.
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Lipid phosphatase assay
The preparation of 3-33 P labelled phosphoinositide substrate has been described previously ([58 59] . To test the lipid phosphatase activity of PTEN against PtdIns(3,4,5)P 3 , lipid vesicles were prepared by sonication containing 100 µM phosphatidylcholine (PC), 1 µM unlabelled diC16 PtdIns(3,4,5)P 3 and a volume of 
Immunocytochemistry
Neuronal cultures treated as described above were fixed using 4% paraformaldehyde for 30 minutes and then blocked with 3% BSA and 0.1% Triton x100 for 1 hour. Fixed neurons were incubated with anti-GFP antibody (1:1,000, Abcam), anti-PTEN antibody (1:500, PTEN138G6 Cell Signaling Technology) or anti-RFP (1:1,000, Cat. n. ab62341 Abcam) antibody diluted in 3% BSA, 1% goat serum and 1% sodium azide followed by incubation with Alexa488, Alexa568 and Alexa647 conjugated secondary antibodies (1:1,000, Invitrogen). Cells were stained with DAPI
(1 µg/ml) for 10 minutes prior to mounting. The soma of the neurons, density and length of the spines were measured using ImageJ and were represented in µm.
Animal procedures
All animal procedures (breeding and sacrifice) were conducted in accordance with local ethical guidelines and approved animal care protocols (Berlin: Institutional Animal Care and Use Committee (IACUC) and the Landesamt für Gesundheit und Soziales (LAGeSO) -license T 0347/11.
